Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Albani

Lenexa, KS Medical Doctor

NPI 1295777464 CMS profile 240873

8551 Bluejacket St, Lenexa, KS 66214

Open in the dashboard

General payments

$4,284

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Albani of Lenexa, KS is reported in the CMS Open Payments database as having received $4,284 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $465 12
2024 General $297 12
2023 General $741 20
2022 General $878 44
2021 General $645 33
2020 General $399 17
2019 General $858 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Albani
  • Kansas median
  • Middle half of Kansas
  • National median

In program year 2025, general payments to Justin Albani were reported at $465. Among 9,119 Kansas profiles paid that year, the median was $162 and the middle half received between $49 and $552.

Show as a table
Year Justin Albani Kansas median Middle half National median
2019 $858 $173 $53–$611 $163
2020 $399 $114 $35–$345 $114
2021 $645 $128 $36–$445 $132
2022 $878 $146 $43–$508 $149
2023 $741 $152 $42–$494 $160
2024 $297 $159 $48–$536 $164
2025 $465 $162 $49–$552 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $860 26 payments
  2. Janssen Biotech, Inc. $393 16 payments
  3. PROCEPT BioRobotics Corporation $390 4 payments
  4. AbbVie, Inc. $367 24 payments
  5. Antares Pharma, Inc. $267 19 payments
  6. Olympus America Inc. $202 6 payments
  7. 180 Medical, Inc. $192 8 payments
  8. Blue Earth Diagnostics Limited $179 10 payments
  9. Novartis Pharmaceuticals Corporation $134 1 payment
  10. KARL STORZ Endoscopy-America $124 4 payments
  11. Other $1,176 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,774 174 payments
  2. Education $509 6 payments
Products named General payments · program years 2019–2025
  1. ERLEADA $393 16 payments
  2. XTANDI $298 15 payments
  3. AQUABEAM ROBOTIC SYSTEM $284 2 payments
  4. XYOSTED $283 20 payments
  5. LUPRON DEPOT $249 16 payments
  6. MYRBETRIQ $211 11 payments
  7. NOCDURNA $197 15 payments
  8. TLANDO $177 13 payments
  9. Axumin $155 9 payments
  10. iTIND System $153 3 payments
  11. Other $1,597 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,953

Median for Urology: 1,053

Drug cost

$130,641

Median for Urology: $101,464

Branded share of claims

21.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 40 $43,019
Gemtesa Vibegron Brand 75 $38,486
Potassium Citrate Er Potassium Citrate Brand 132 $14,295
Tamsulosin Hcl Generic 770 $12,857
Finasteride Generic 401 $6,616
Silodosin Generic 47 $3,659
Testosterone Generic 21 $2,930
Alfuzosin Hcl Er Alfuzosin Hcl Brand 86 $2,125
Tadalafil Generic 18 $1,217
Estradiol Generic 13 $1,071

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$229,446

Of which drugs: $16,419

Medicare patients

805

Average age 75

Services billed

5,642

117 women, 688 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 39%
Arthritis 39%
Ischemic heart disease 36%
Diabetes 31%
Chronic kidney disease 23%
Atrial fibrillation 22%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 11 102 $14,515
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 17 31 $58
Injection, propofol, 10 mg J2704 Office 17 660 $54
Injection, ceftriaxone sodium, per 250 mg J0696 Office 15 60 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $53
$53 — —
LUPRON DEPOT
  • AbbVie, Inc. $38
$38 — 102
XYOSTED
  • Antares Pharma, Inc. $31
$31 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $30
$30 75 —
POSLUMA
  • Blue Earth Diagnostics Limited $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record